BR112018067454A2 - regime de dosagem para o tratamento de exacerbações agudas de doença pulmonar obstrutiva crônica - Google Patents

regime de dosagem para o tratamento de exacerbações agudas de doença pulmonar obstrutiva crônica

Info

Publication number
BR112018067454A2
BR112018067454A2 BR112018067454A BR112018067454A BR112018067454A2 BR 112018067454 A2 BR112018067454 A2 BR 112018067454A2 BR 112018067454 A BR112018067454 A BR 112018067454A BR 112018067454 A BR112018067454 A BR 112018067454A BR 112018067454 A2 BR112018067454 A2 BR 112018067454A2
Authority
BR
Brazil
Prior art keywords
treatment
pulmonary disease
chronic obstructive
obstructive pulmonary
dosage regimen
Prior art date
Application number
BR112018067454A
Other languages
English (en)
Portuguese (pt)
Inventor
Orford Colin
Farrell Colm
Clarke Cyril
Parkin Jacqueline
De Buck Stefan
Original Assignee
Mereo Biopharma 1 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mereo Biopharma 1 Ltd filed Critical Mereo Biopharma 1 Ltd
Publication of BR112018067454A2 publication Critical patent/BR112018067454A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112018067454A 2016-03-08 2016-03-08 regime de dosagem para o tratamento de exacerbações agudas de doença pulmonar obstrutiva crônica BR112018067454A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2016/050636 WO2017153702A1 (en) 2016-03-08 2016-03-08 Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease

Publications (1)

Publication Number Publication Date
BR112018067454A2 true BR112018067454A2 (pt) 2019-01-15

Family

ID=55586330

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018067454A BR112018067454A2 (pt) 2016-03-08 2016-03-08 regime de dosagem para o tratamento de exacerbações agudas de doença pulmonar obstrutiva crônica

Country Status (9)

Country Link
US (2) US10603306B2 (cg-RX-API-DMAC7.html)
JP (1) JP6741774B2 (cg-RX-API-DMAC7.html)
KR (2) KR20180118667A (cg-RX-API-DMAC7.html)
AU (1) AU2016397047B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018067454A2 (cg-RX-API-DMAC7.html)
CA (1) CA3016488C (cg-RX-API-DMAC7.html)
MX (1) MX385717B (cg-RX-API-DMAC7.html)
RU (1) RU2713203C1 (cg-RX-API-DMAC7.html)
WO (1) WO2017153702A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017153702A1 (en) * 2016-03-08 2017-09-14 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
GB201612238D0 (en) 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide
GB201612240D0 (en) 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
HUE054266T2 (hu) 2017-12-11 2021-08-30 Mereo Biopharma 1 Ltd 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-N-ciklopropil-4-metilbenzamid alkalmazása krónikus obstruktív tüdõbetegség akut megjelenésének megelõzésében
KR102899004B1 (ko) * 2017-12-11 2025-12-12 메레오 바이오파마 1 리미티드 만성 폐쇄성 폐 질환의 급성 악화의 치료에서의 3-[5-아미노-4-(3-시아노벤조일)-피라졸-1-일]-n-시클로프로필-4-메틸벤즈아미드의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US6598603B1 (en) 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
CN1832928B (zh) 2003-06-26 2012-07-04 诺瓦提斯公司 以5元杂环为基础的p38激酶抑制剂
TWI439284B (zh) 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 用於治療TNFα相關失調症之多重可變劑量療法
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
US20050277602A1 (en) 2004-05-21 2005-12-15 Grunstein Michael M Methods employing agonists of P38 map kinase for the treatment of asthma
EP1987022A1 (en) 2006-02-10 2008-11-05 Pfizer Products Inc. Pyridinone pyrazole urea and pyrimidinone pyrazole urea derivatives
GB0603684D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
ES2605942T3 (es) * 2012-03-20 2017-03-17 Mereo Biopharma 1 Limited Uso de un derivado de pirazol en el tratamiento de exacerbaciones agudas de enfermedad pulmonar obstructiva crónica
WO2017153702A1 (en) * 2016-03-08 2017-09-14 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
US10617674B2 (en) * 2016-03-08 2020-04-14 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of inflammatory conditions

Also Published As

Publication number Publication date
US20190060279A1 (en) 2019-02-28
JP6741774B2 (ja) 2020-08-19
US20200281896A1 (en) 2020-09-10
MX385717B (es) 2025-03-18
US11129810B2 (en) 2021-09-28
US10603306B2 (en) 2020-03-31
CA3016488A1 (en) 2017-09-14
WO2017153702A1 (en) 2017-09-14
CA3016488C (en) 2023-04-11
JP2019507786A (ja) 2019-03-22
AU2016397047A1 (en) 2018-09-06
KR102762199B1 (ko) 2025-02-07
KR20240101698A (ko) 2024-07-02
KR20180118667A (ko) 2018-10-31
MX2018010782A (es) 2019-01-10
AU2016397047B2 (en) 2022-04-07
RU2713203C1 (ru) 2020-02-04

Similar Documents

Publication Publication Date Title
IL264210A (en) High-strength oral cannabinoid dosage forms
ZA201800022B (en) Substituted heterocyclyl derivatives as cdk inhibitors
CL2018002727A1 (es) Medicina obtenida mediante la combinación de agonista fxr y arb
MX2017009449A (es) Inhibidor jak.
BR112017027843A2 (pt) formulações farmacêuticas compreendendo tenofovir e emtricitabina
UY39706A (es) Derivados de (1hindol- 3-il)-2-(4-cloro-2-metoxi-fenil)-2-((3-metoxi-5-(metilsulfonil) fenil)amino)etanona como inhibidores de la replicación del virus del dengue
AR096543A1 (es) INHIBIDORES DE QUINASA PI3 d Y g SELECTIVOS DUALES
MX2017016524A (es) Sistemas de administracion para liberacion controlada de farmacos.
AR100663A1 (es) Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona
PH12014502107B1 (en) Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease
MX385717B (es) Regimen de dosificacion para el tratamiento de exacerbaciones agudas de enfermedad pulmonar obstructiva cronica.
CY1123576T1 (el) Συμπυκνωμενα παραγωγα θειοφαινιου χρησιμα ως αναστολεις του napi-iib
PH12019501955A1 (en) Tri-cycle compound and applications thereof
SV2016005313A (es) Derivados de carboxamida
CY1122755T1 (el) Eξισορροπημενες απο αποψη φυσιολογιας ενεσιμες μορφοποιησεις φωσνετουπιταντης
BR112018067784A2 (pt) regime de dosagem para o tratamento de exacerbações agudas de condições inflamatórias
MY182008A (en) Pharmaceutical formulations
MX381526B (es) Agente para suprimir el progreso de o para mejorar la enfermedad renal crónica.
MX2016016491A (es) Derivados de o-alquil-bencilidenguanidina y uso terapeutico para el tratamiento de trastornos asociados con acumulacion de proteinas mal plegadas.
HK1245131A1 (zh) 用於治疗炎症性疾病的包含十六酰胺乙醇pea和番茄红素的组合物
CL2013002325A1 (es) Compuestos derivados de 4-amino-2-butenamidas, inhibidores de catepsina c; composicion farmaceutica que los comprende; procedimiento de preparacion de la composicion farmaceutica; uso del compuesto en el tratamiento de enfermedad pulmonar obstructiva cronica.
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
BR112018003335A2 (pt) composições farmacêuticas compreendendo 3-(5-amino-2-metil-4-oxo-4h-quinazolina-3-il)-piperidina-2,6-diona
EA201692013A1 (ru) Новое применение n,n-бис-2-меркаптоэтил-изофталамида
AR109209A1 (es) Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]